CSIR-Laxai receive DCGI nod to begin trials for Colchicine in Covid patients1 min read 12 Jun 2021, 12:19 PM IST
India is one of the largest producers of Colchicine, and can provide it to the patients at an affordable cost if the clinical trials are successful
The trials are expected to be completed in 8-10 weeks
Drug Controller General of India (DCGI) has given its approval to clinical trials for anti-inflammatory drug Colchicine in treating Covid-19 patients.
Select your Category